IRVINE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that four Trials in Progress Posters highlighting cretostimogene, in addition to the recently announced late breaking abstract on BOND-003, will be presented at the Society of Urologic Oncology (SUO) 25th Annual Meeting taking place at the Sheraton Dallas Hotel in Dallas, TX, from December 4 - 6, 2024. Details on the late-breaking abstract and posters are as follows: Late-Breaking Abstract: Topline Results from BOND

- Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology (SUO) 25th Annual Meeting - IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the third quarter ended September 30, 2024, and provided business updates. "This quarter, we've continued to make significant advancements across our pipeline to bring forward a potential backbone bladder-spa

– Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer 2024 – – Encouraging data adds to the body of evidence supporting potential use of cretostimogene as a backbone bladder-sparing therapeutic for bladder cancer – IRVINE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the publication in Nature Medicine of Phase 1b investigator-sponsored study results evaluating intravesical cretostimogene grenadeno

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to participate in a fireside chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90

– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature Medicine and featured at ASCO 2024 – – Announced 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint in the CORE-001 study – – Demonstrated 75.2% CR rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in Cretostimogene Monotherapy BOND-003 study – – Initiated and dosed first patient in Expanded Access Program for Cretostimogene Grenadenorepvec; Enrollment ongoing –  IRVINE, Calif., Aug. 08, 2024 (GLOBE NE

IRVINE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that it has initiated an Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) and meet certain program eligibility criteria. The first patient has been dosed in the EAP and enrollment in the study is ongoing. "Bladder cancer is a highly recurrent disease with few treatment options a

– Final positive CORE-001 safety and efficacy findings were published simultaneously online by Nature Medicine and featured at ASCO 2024 – – 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint of the phase 2 study – IRVINE, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the publication in Nature Medicine of final results from the Company's CORE-001 Phase 2 trial of cretostimogene plus pembrolizumab in BCG-unres

IRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) with Carcinoma in Situ (CIS). The data will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting from May 31-June 4, in Chicago, IL. "There is a signifi

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-Risk NMIBC (IR-NMIBC)Final Results from CORE-001 Phase 2 Clinical Trial of Cretostimogene in Combination with Pembrolizumab in BCG-Unresponsive HR-NMIBC will be presented at ASCO 2024 Completed Oversubscribed and Upsized $437 Million Initial Public Offering that Extends Expected Runway Through 2027 IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical b

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT - IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), showed that 75.2% of patients (79 out of 105 [95% confidence interval (CI), 65-83]) achieved a complete response (CR) at any time, as of the cutoff date of April 1, 202

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

4 - CG Oncology, Inc. (0001991792) (Issuer)

UBS initiated coverage of CG Oncology with a rating of Buy and set a new price target of $60.00

RBC Capital Mkts initiated coverage of CG Oncology with a rating of Outperform and set a new price target of $66.00

ROTH MKM initiated coverage of CG Oncology with a rating of Buy and set a new price target of $65.00

BofA Securities initiated coverage of CG Oncology with a rating of Buy and set a new price target of $65.00

Cantor Fitzgerald initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $75.00

Goldman initiated coverage of CG Oncology with a rating of Neutral and set a new price target of $42.00

Morgan Stanley initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $55.00

4/A - CG Oncology, Inc. (0001991792) (Issuer)

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT - IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), showed that 75.2% of patients (79 out of 105 [95% confidence interval (CI), 65-83]) achieved a complete response (CR) at any time, as of the cutoff date of April 1, 202

SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

SC 13G - CG Oncology, Inc. (0001991792) (Subject)

SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)

SC 13G - CG Oncology, Inc. (0001991792) (Subject)

8-K - CG Oncology, Inc. (0001991792) (Filer)

144 - CG Oncology, Inc. (0001991792) (Subject)

144 - CG Oncology, Inc. (0001991792) (Subject)

10-Q - CG Oncology, Inc. (0001991792) (Filer)

8-K - CG Oncology, Inc. (0001991792) (Filer)

8-K - CG Oncology, Inc. (0001991792) (Filer)

8-K - CG Oncology, Inc. (0001991792) (Filer)

10-Q - CG Oncology, Inc. (0001991792) (Filer)

8-K - CG Oncology, Inc. (0001991792) (Filer)

10-K - CG Oncology, Inc. (0001991792) (Filer)

9 analysts have expressed a variety of opinions on CG Oncology (NASDAQ:CGON) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 7 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 5 2 0 0 0 3M Ago 1 0 0 0 0 Analysts have recently evaluated CG Oncology and provided 12-month price targets. The average target is $68.33, accompanied by a high estimate of $75.00 and a low estimate of $50.00. This current

B of A Securities analyst Charlie Yang initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Target of $65.

Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results. SAIC reported a 9% revenue decline year over year in the fiscal first quarter of 2025 to $1.847 billion, marginally beating the analyst consensus estimate of $1.844 billion. Adjusted EPS of $1.92 was in line with the analyst consensus estimate, according to data from Benzinga Pro. SAIC shares dipped 11% to $119.91 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Microbot Medical Inc. (NASDAQ:MBOT) jumped 92.5% to $1.9301 after the company received FDA approval to proceed with its pivotal human clinical trial. Bio-Pa

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday. Shares of Stericycle, Inc. (NASDAQ:SRCL) rose sharply during Monday's session after the company inked a deal to be acquired by Waste Management Inc. (NYSE:WM) for approximately $7.2 billion, including debt. Stericycle shares climbed 15% to $59.28 on Monday. Here are some other big stocks recording gains in today’s session. GameStop Corp. (NYSE:GME) shares jumped 34.5% to $31.13 after Roaring Kitty on a Reddit post, shared his position on the stock. MarineMax, Inc. (NYSE:HZO) jumped 27% to $36.16. OneWater Marine Inc. is reportedly said to be in advanced discussions to acquire MarineMax. L

HC Wainwright & Co. analyst Andres Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $75 price target.

In the latest quarter, 10 analysts provided ratings for CG Oncology (NASDAQ:CGON), showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 4 1 0 0 Last 30D 1 0 0 0 0 1M Ago 3 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 2 1 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $64.7, with a high estimate of $75.00 and a low estimate of $42.00. Marking an increase of 50.47%, the cur

Goldman Sachs analyst Corinne Johnson upgrades CG Oncology (NASDAQ:CGON) from Neutral to Buy and raises the price target from $43 to $50.

Goldman Sachs analyst Corinne Johnson upgrades CG Oncology (NASDAQ:CGON) from Neutral to Buy and announces $50 price target.